Package Leaflet: Information for the User
Atosiban Altan 6.75 mg/0.9 ml Solution for Injection EFG
Atosiban
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
Contents of the Package Leaflet:
Atosiban Altan contains atosiban. Atosiban may be used to delay premature birth of your baby. Atosiban is used in adult pregnant women, from the 24th week to the 33rd week of pregnancy.
Atosiban works by making the contractions of your uterus (womb) less strong. It also makes the contractions happen less often. This happens because it prevents the natural hormone called "oxytocin", which causes the uterus to contract, from working.
You should not be given Atosiban Altan
Do not use Atosiban Altan if you are affected by any of these conditions. If you are not sure, tell your doctor, midwife or pharmacist before you are given Atosiban Altan.
Warnings and precautions
Talk to your doctor, midwife or pharmacist before you are given atosiban:
If you have any of these conditions (or are not sure), tell your doctor, midwife or pharmacist before you are given atosiban.
Children and adolescents
Atosiban has not been studied in pregnant women under 18 years of age.
Using Atosiban Altan with other medicines
Tell your doctor, midwife or pharmacist if you are taking, have recently taken or might take any other medicines.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, breast-feeding should be stopped during treatment with atosiban.
Atosiban Altan will be given to you in a hospital by a doctor, nurse or midwife. They will decide how much you need. They will also make sure that the solution is clear and free of particles.
Atosiban will be given into a vein (intravenously) in three stages:
The total duration of treatment should not be more than 48 hours.
Further treatments with atosiban can be given if you have contractions again. Treatment with atosiban can be repeated up to three times more.
During treatment with atosiban, your contractions and your baby's heart rate can be monitored.
It is recommended not to repeat treatment more than three times during a pregnancy.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The side effects seen in mothers were generally mild. There are no known side effects on the fetus or newborn.
The following side effects may occur with this medicine:
Very common(affects more than 1 in 10 people)
Common(affects less than 1 in 10 people)
Uncommon(affects less than 1 in 100 people)
Rare(affects less than 1 in 1,000 people)
You may experience difficulty breathing or fluid in the lungs (pulmonary oedema), particularly if you are pregnant with more than one baby and/or are taking other medicines that may delay the birth of your baby, such as medicines used for high blood pressure.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Agency website: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date is the last day of the month shown.
Store in a refrigerator (2°C - 8°C).
Store in the original package to protect from light.
Once the ampoule is opened, the product should be used immediately.
Do not use this medicine if you notice that it contains particles or discolouration of the contents before administration.
Composition of Atosiban Altan
The active substance is atosiban.
Each ampoule (0.9 ml solution for injection) contains 6.75 mg of atosiban (as acetate).
The other ingredients are: mannitol, hydrochloric acid and water for injections.
Appearance of Atosiban Altan and contents of the pack
Atosiban Altan 6.75 mg/0.9 ml solution for injection is a clear, colourless solution without particles. One pack contains a glass ampoule (2 ml) which contains 0.9 ml of solution.
Marketing Authorisation Holder
Altan Pharmaceuticals, S.A.
C/Cólquide, Nº6, Portal 2, 1ª Planta, Oficina F. Edificio Prisma
28230 Las Rozas (Madrid)
Spain
Manufacturer
ALTAN PHARMACEUTICALS, S.A
Avda de la Constitución 198-199, Polígono Industrial Monte Boyal
45950 Casarrubios del Monte (Toledo)
Spain
This medicine is authorised in the Member States of the EEA under the following names:
Spain: | Atosiban Altan 6.75 mg/0.9 ml solution for injection EFG |
Belgium: | Atosiban Altan 6.75 mg/0.9 ml Solution injectable |
France: | Atosiban Altan 6.75 mg/0.9 ml Solution injectable |
Germany: | Atosiban Ibisqus 6.75 mg/0.9 ml Injektionslösung |
Austria: | Atosiban Altan 6.75 mg/0.9 ml Injektionslösung |
Italy: | Atosiban Ibisqus |
United Kingdom: | Atosiban 6.75 mg/0.9 ml solution for injection |
This leaflet was last revised in: October 2020
"Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/".
This information is intended only for healthcare professionals (see also section 3):
Instructions for use:
Before using Atosiban Altan, the solution should be examined to ensure it is clear and free of particles.
Atosiban Altan is administered intravenously in three successive stages:
The total duration of treatment should not be more than 48 hours. Further cycles of treatment with Atosiban Altan can be given if contractions occur again. It is recommended not to repeat treatment more than three times during a pregnancy.